Figure 1From: Minimal percentage of dose received by 90% of the urethra (%UD90) is the most significant predictor of PSA bounce in patients who underwent low-dose-rate brachytherapy (LDR-brachytherapy) for prostate cancer PSA bounce (0.1 ng/mL)-free rate in all patients stratified by treatment procedure (neoadjuvant/ adjuvant ADT and monotherapy/ combination with EBRT). Back to article page